Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.

[1]  M. Raffeld,et al.  Identification of an Immunogenic Subset of Metastatic Uveal Melanoma , 2015, Clinical Cancer Research.

[2]  M. Smylie,et al.  A phase 2 study of tremelimumab in patients with advanced uveal melanoma , 2015, Melanoma research.

[3]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[4]  S. Rosenberg,et al.  Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Enk,et al.  Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma , 2015, PloS one.

[6]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[7]  G. Linette,et al.  Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. , 2014, JAMA.

[8]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[9]  S. Rosenberg,et al.  Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions , 2014, Clinical Cancer Research.

[10]  P. Ascierto,et al.  Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  A. Giobbie-Hurder,et al.  Clinical activity of ipilimumab for metastatic uveal melanoma , 2013, Cancer.

[12]  C. Blank,et al.  Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O) , 2013, Acta oncologica.

[13]  A. Gesierich,et al.  Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives , 2013, Cancer medicine.

[14]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[15]  Seth M Steinberg,et al.  Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Jimmy Lin,et al.  Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.

[17]  J. Larkin,et al.  Ipilimumab activity in advanced uveal melanoma , 2013, Melanoma research.

[18]  A. Bowcock,et al.  Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma , 2013, Nature Genetics.

[19]  J. Niederkorn.  Ocular Immune Privilege and Ocular Melanoma: Parallel Universes or Immunological Plagiarism? , 2012, Front. Immun..

[20]  J. Harbour.  The genetics of uveal melanoma: an emerging framework for targeted therapy , 2012, Pigment cell & melanoma research.

[21]  J. Kirkwood,et al.  Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[23]  R. Plummer,et al.  Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy , 2011, Cancer Immunology, Immunotherapy.

[24]  A. Bowcock,et al.  Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas , 2010, Science.

[25]  J. O'Brien,et al.  Mutations in GNA11 in uveal melanoma. , 2010, The New England journal of medicine.

[26]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[27]  E. Simpson,et al.  Frequent somatic mutations of GNAQ in uveal melanoma and blue nevi , 2008, Nature.

[28]  Ahmedin Jemal,et al.  Incidence of noncutaneous melanomas in the U.S. , 2005, Cancer.

[29]  S. Rosenberg,et al.  Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred , 2022 .

[30]  K. Kopecky,et al.  Evaluation of fludarabine phosphate in malignant melanoma , 1991, Investigational New Drugs.

[31]  R. Scully,et al.  Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. , 2001, Archives of ophthalmology.

[32]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  W. Fridman,et al.  Interleukin-2 therapy for metastatic uveal melanoma. , 1992, European journal of cancer.

[34]  C. Presant,et al.  A randomized comparison of cyclophosphamide, DTIC with or without piperazinedione in metastatic malignant melanoma , 1982, Cancer.